VERACYTE, INC. (VCYT) Stock Price, Financials & Summary

Price chart

Oct 6Oct 9Oct 14Oct 19Oct 22Oct 27Oct 30Nov 4

Key dataNov 4, 2026

Open$52.35

From 52W high−14.41%

Volume762393.00

Market cap$4.16B

P/E (TTM)36.0x

P/S (TTM)7.4x

Div yield—

Key dataNov 4, 2026

Open

$52.35

From 52W high

−14.41%

Volume

762393.00

Market cap

$4.16B

ValuationView details →

P/E (Fwd)

27.9x

EV/EBITDA

28.6x

P/E (TTM)

36.0x

RSI (14)

62.2

MomentumView details →

1D Return

+2.96%

YTD Return

+21.15%

SummaryUpdated Jun 1, 2026

Veracyte, Inc. (NASDAQ:VCYT) is a molecular diagnostics company founded in 2006 and headquartered in South San Francisco, California. Originally incorporated as Calderome, Inc., the company changed its name to Veracyte in March 2008 and went public in October 2013. Veracyte has evolved from a single-product thyroid cancer diagnostics company into a diversified genomic testing platform serving multiple cancer types including prostate, breast, lung, and colon cancers.

Ask drillr about VERACYTE, INC. →

ValuationView details →

P/E (Fwd)

27.9x

P/E (TTM)

36.0x

EV/EBITDA

28.6x

EV/Sales

6.6x

P/S (TTM)

7.4x

P/B (TTM)

3.0x

ProfitabilityView details →

Gross Margin

72.09%

Net Margin

20.37%

EBITDA Margin

23.10%

ROE (TTM)

8.25%

ROA (TTM)

7.70%

Asset Turnover

0.38x

GrowthView details →

Revenue YoY

+17.28%

EPS YoY

+314.39%

FCF YoY

+97.05%

Revenue CAGR 3Y

+20.37%

EPS CAGR 3Y

+162.50%

EBITDA YoY

+184.04%

MomentumView details →

1D Return

+2.96%

YTD Return

+21.15%

1Y Return

+10.78%

RSI (14)

62.2

vs 50D SMA

+13.67%

vs 200D SMA

+18.75%

Capital & dividendView details →

Debt/Equity

0.03x

Current Ratio

9.16x

Quick Ratio

8.80x

Div Yield

—

Div Rate

—

Div Growth 1Y

—

EarningsView details →

EPS (Actual)

$0.54

EPS Surprise

31.61%

Beats (12Q)

11/12

Next Q EPS Est

$0.45

Avg Surprise (4Q)

37.60%

Rev Surprise

3.96%

Financials snapshotView financials →

Revenue (TTM)

561.90M

Net Income (TTM)

114.48M

Op. CF (TTM)

178.38M

Next earningsNov 4, 2026 →

Latest newsMore news →

Veracyte announced that six studies involving its genomic tests will be presented at the ESMO Congress 2026 in Madrid from October 23 to 27.16d ago

VERACYTE, INC. secured Medicare reimbursement for its Prosigna Breast Risk of Recurrence Test.19d ago

Similar companies

Ocumension Therapeutics01477.HK Arcutis Biotherapeutics, Inc.ARQT Edgewise Therapeutics, Inc.EWTX Abbisko Cayman Limited02256.HK Adaptive Biotechnologies CorporationADPT Liquidia CorporationLQDA Find similar companies →

Latest newsMore news →

Veracyte announced that six studies involving its genomic tests will be presented at the ESMO Congress 2026 in Madrid from October 23 to 27.16d ago VERACYTE, INC. secured Medicare reimbursement for its Prosigna Breast Risk of Recurrence Test.19d ago